A phase 1 study of ADI-001: Anti-CD20 CAR-engineered allogeneic gamma delta (γδ) T cells in adults with B-cell malignancies.

出版年份 2022 全文链接

标题

作者

关键词

出版物

Volume 40, Issue 16_suppl, Pages 7509-7509

出版商

American Society of Clinical Oncology (ASCO)

发表日期

2022-06-07

DOI

10.1200/jco.2022.40.16_suppl.7509

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now